| 发明名称 |
Dapagliflozin og farmasøytisk akseptable salter derav |
| 摘要 |
An SGLT2 inhibiting compound is provided having the formula A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent. |
| 申请公布号 |
NO2013007(I2) |
申请公布日期 |
2014.06.02 |
| 申请号 |
NO20130000007C |
申请日期 |
2013.04.12 |
| 申请人 |
ASTRAZENECA AB |
发明人 |
|
| 分类号 |
C07H7/04;A61K31/155;A61K31/22;A61K31/351;A61K31/365;A61K31/70;A61K31/7034;A61K45/00;A61K45/06;A61P3/04;A61P3/06;A61P3/10;A61P5/48;A61P9/10;A61P9/12;A61P13/12;A61P17/02;A61P25/00;A61P27/00;C07C43/225;C07C45/46;C07C49/84;C07D309/10;C07H15/20;C07H15/203 |
主分类号 |
C07H7/04 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
